Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Heron Therapeutics (HRTX) over the last 12 years, with Dec 2024 value amounting to $233.1 million.

  • Heron Therapeutics' Liabilities and Shareholders Equity rose 12.76% to $248.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $949.9 million, marking a year-over-year increase of 8.03%. This contributed to the annual value of $233.1 million for FY2024, which is 4.78% up from last year.
  • Heron Therapeutics' Liabilities and Shareholders Equity amounted to $233.1 million in FY2024, which was up 4.78% from $222.5 million recorded in FY2023.
  • Heron Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $353.6 million for FY2020, and its period low was $222.5 million during FY2023.
  • Its 3-year average for Liabilities and Shareholders Equity is $235.5 million, with a median of $233.1 million in 2024.
  • Per our database at Business Quant, Heron Therapeutics' Liabilities and Shareholders Equity slumped by 31.05% in 2020 and then rose by 4.78% in 2024.
  • Yearly analysis of 5 years shows Heron Therapeutics' Liabilities and Shareholders Equity stood at $353.6 million in 2020, then dropped by 13.53% to $305.7 million in 2021, then fell by 17.91% to $251.0 million in 2022, then decreased by 11.33% to $222.5 million in 2023, then grew by 4.78% to $233.1 million in 2024.